FDA Proposes to Exclude Semaglutide, Tirzepatide, and Liraglutide from 503B Bulks List, Citing No Clinical Need

What this means for your practice

This proposal is a significant development for telehealth brands, medspas, and weight loss clinics that have built service lines around compounded GLP-1 medications sourced from 503B outsourcing facilities. If finalized, this rule would close the primary regulatory pathway that allowed high-volume compounded semaglutide, tirzepatide, and liraglutide to flow through the market. Operators should immediately audit their current compounded GLP-1 supply chains, assess patient volume relying on 503B-sourced products, and develop contingency plans for transitioning patients to FDA-approved branded drugs. This is also the time to submit formal comments to the FDA docket before the June 29, 2026 deadline if your practice has clinical evidence of patient need that could inform the agency's final decision. Compliance teams should not wait for a final rule — proactive planning now is essential.

FDA Moves to Block Compounded GLP-1s from 503B Outsourcing Facilities

On April 30, 2026, the U.S. Food and Drug Administration announced a proposed rule that would exclude semaglutide, tirzepatide, and liraglutide from the 503B bulks list — a move that would effectively shut down the primary legal pathway through which outsourcing facilities have been compounding these blockbuster GLP-1 medications at scale.

For the telehealth, medspa, and weight management sectors, this is one of the most consequential regulatory developments of 2026.

What Is the 503B Bulks List?

Under Section 503B of the Federal Food, Drug, and Cosmetic Act (FD&C Act), licensed outsourcing facilities — large-scale compounders registered with the FDA — are permitted to produce compounded drugs without patient-specific prescriptions, enabling them to supply healthcare facilities and practices at volume.

However, there is a critical legal constraint: outsourcing facilities generally cannot compound drugs using bulk drug substances unless those substances appear on the FDA's 503B bulks list, or the compounded drug is on the FDA's drug shortage list at the time of compounding, distribution, and dispensing.

The 503B bulks list is therefore the gatekeeper. Inclusion on the list signals that FDA has found a clinical need for outsourcing facilities to compound a particular substance. Exclusion — or removal — from that list eliminates the lawful basis for bulk compounding of that drug by 503B facilities under most circumstances.

What FDA Is Proposing — and Why

After reviewing nominations submitted for semaglutide, tirzepatide, and liraglutide, the FDA stated it did not identify a clinical need for outsourcing facilities to compound these three drugs from bulk substances.

FDA Commissioner Marty Makary, M.D., M.P.H., framed the decision directly:

> *"When FDA-approved drugs are available, outsourcing facilities cannot lawfully compound using bulk drug substances unless there is a clear clinical need. This action reflects our responsibility to protect patients and preserve the integrity of the drug approval process while continuing to provide a transparent, science-based pathway for public input."*

The FDA's standard for inclusion on the 503B bulks list is grounded in patient safety and medical necessity under the law. In this case, the agency found the evidence submitted during the nomination process insufficient to justify inclusion for any of these three substances.

The FDA has emphasized that this is currently a proposal, not a final rule. Interested parties have until June 29, 2026 to submit comments electronically through the FDA docket. The agency has stated it will consider submitted comments before making a final determination.

Why This Matters: The 503B Channel and the GLP-1 Market

Over the past several years, compounded GLP-1 medications — particularly semaglutide and tirzepatide — became widely available through 503B outsourcing facilities, largely enabled by FDA drug shortage designations and the 503B compounding framework. Telehealth platforms, weight loss clinics, medspas, and functional medicine practices built entire service lines around access to these lower-cost compounded alternatives.

The FDA had previously acted to remove semaglutide and tirzepatide from its shortage list, which narrowed one compounding pathway. This new proposal targets the bulk substance compounding pathway under 503B directly — addressing the remaining legal route that some outsourcing facilities have used to continue supplying compounded GLP-1s.

If finalized, this exclusion would mean:

• 503B outsourcing facilities could no longer lawfully compound semaglutide, tirzepatide, or liraglutide from bulk substances under standard conditions
• Practices sourcing compounded GLP-1s from 503B facilities would lose access to that supply channel
• Patient populations currently on compounded GLP-1 regimens would need transition plans

What Healthcare Operators Should Do Now

1. Audit Your GLP-1 Supply Chain Determine whether your current compounded GLP-1 products are sourced from 503B outsourcing facilities. If so, this proposal directly affects your supply pipeline.

2. Assess Patient Volume and Transition Risk Quantify how many active patients are on compounded semaglutide, tirzepatide, or liraglutide. Begin planning for potential transitions to FDA-approved branded therapies if the rule is finalized.

3. Consider Submitting Public Comments The comment period closes June 29, 2026. If your practice has clinical documentation supporting patient need for compounded GLP-1 formulations — such as documented inability to access or tolerate FDA-approved versions — submitting that evidence to the docket is a legitimate and important step. The FDA has stated it will consider all submitted comments.

4. Do Not Wait for a Final Rule Regulatory finalization can happen faster than anticipated. Compliance-forward operators should begin contingency planning now rather than after a final exclusion is published.

5. Consult Legal and Compliance Counsel The intersection of 503B compounding law, shortage list status, and state pharmacy regulations is complex. Work with qualified healthcare regulatory counsel to assess your specific exposure.

The Regulatory Trajectory

This proposal is consistent with FDA's broader posture of tightening oversight of compounded GLP-1 medications following the resolution of shortage designations for these drugs. The agency has repeatedly signaled that compounding is a limited exception to — not a substitute for — the FDA drug approval process.

For telehealth and medspa operators who built their GLP-1 programs on compounding access, the regulatory window has been narrowing steadily. This proposal represents a potentially decisive step in that trend.

*Source: FDA Press Announcement, April 30, 2026. Official source: http://www.fda.gov/news-events/press-announcements/fda-proposes-exclude-semaglutide-tirzepatide-and-liraglutide-503b-bulks-list*

Source: FDA — FDA Proposes to Exclude Semaglutide, Tirzepatide, and Liraglutide on 503B Bulks List · Thu, 30 Apr 2026 09:18:42 EDT